3S43

HIV-1 protease triple mutants V32I, I47V, V82I with antiviral drug amprenavir

Summary for 3S43

Entry DOI	10.2210/pdb3s43/pdb
Related	3NU3 3NU4 3S53 3S54 3S56
Descriptor	Protease, {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER, IODIDE ION, ... (6 entities in total)
Functional Keywords	amprenavir, hiv/aids, drug resistance, aspartic protease, molecular recognition, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological source	Human immunodeficiency virus 1 More
Total number of polymer chains	2
Total formula weight	24357.57
Authors	Wang, Y.-F.,Tie, Y.-F.,Weber, I.T. (deposition date: 2011-05-18, release date: 2012-03-21, Last modification date: 2023-09-13)
Primary citation	Tie, Y.,Wang, Y.F.,Boross, P.I.,Chiu, T.Y.,Ghosh, A.K.,Tozser, J.,Louis, J.M.,Harrison, R.W.,Weber, I.T. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci., 21:339-350, 2012 Cited by PubMed: 22238126 DOI: 10.1002/pro.2019 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.26 Å)

Structure validation